Numab Therapeutics Appoints Dr. Rajesh Chopra as Chief Scientific Officer to Advance its Proprietary Multispecific Antibody Pipeline
Appointment brings extensive experience spanning drug discovery, translational medicine, clinical development and scientific leadership
HORGEN, Switzerland, October 1, 2026 – Numab Therapeutics (“Numab”), a biotechnology company advancing a proprietary pipeline of multispecific antibodies in immunology and oncology, today announced the appointment of Rajesh Chopra, M.D., PhD, as Chief Scientific Officer.
